ArticleCureus2025
Expression of CD44 and Its Correlation With Clinicopathological Factors in Oral and Oropharyngeal Carcinoma: A Retrospective Immunohistochemical Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasensitive detection of oral cancer biomarkers CD63 and CD44 in exosomes using janus particles: a rotational diffusometry-based assay.The Saudi dental journal · 2026Article
- Identification and characterization of stem cells in three different oral structures by immunohistochemistry. AnJournal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD44 is a cancer stem cell marker (CSC), which plays a crucial role in cell-to-cell and cell-to-matrix adhesion and is responsible for angiogenesis, invasion, and migration in oral and oropharyngeal cancer.
objectivesThe primary objective of the study was to assess the expression of CD44 in oral and oropharyngeal carcinoma using immunohistochemistry and compare the expression of CD44 in different histological grades of oral and oropharyngeal squamous cell carcinoma (OOSCC). The secondary objective was to correlate the prognosis with the expression. MATERIAL AND
methodsBased on the histopathological diagnosis, we retrieved OOSCC paraffin-embedded blocks from the archives of the Department of Pathology, Maharani Laxmi Bai Medical College, Jhansi (UP), India, reported from June 2023 to July 2024. We evaluated sections from 31 paraffin blocks of well-differentiated OOSCC, 33 moderately differentiated OOSCC, and six poorly differentiated OSCC for CD44 immunostaining. The immunohistochemical expression of CD44 was studied in these tissues and graded based on the intensity of staining. The difference in immune expression of CD44 between different grades was analyzed. The association of CD44 with all the variables was calculated and interpreted by applying the chi-square test and a p-value <0.05 was taken as significant
resultsWe found that all 70 cases of OOSCC showed immunopositivity with CD44 with varying staining intensities. In our study, 33 cases exhibited strong staining intensity, 31 cases were of moderate staining intensity, and six cases exhibited weak to poor staining intensity. Out of 31 well-differentiated of OOSCC, 29 case showed strong staining intensity and two cases showed moderate staining intensity. However, in 33 cases of moderately differentiated SCC, only four cases showed strong staining intensity, and none of the poorly differentiated OOSCC cases showed strong staining intensity. Our findings of grade versus staining intensity of CD44 expression by tumor cells in OOSCC came out to be statistically significant (p < 0.05).
conclusionThe expression of CD44 was noted to decrease from well-differentiated to poorly differentiated OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.